Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVx201
- Development stage
- Unknown
- Lead developer
- Rational Vaccines
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
RVx201 is a live attenuated, rationally engineered therapeutic vaccine candidate developed for the treatment of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections. The vaccine is designed to be interferon-sensitive by mutating a specific viral protein that normally allows HSV to evade the host immune response, thereby enhancing immunogenicity and reducing the virus's ability to inhibit immune defenses. Preclinical studies have shown that RVx201 significantly reduces recurrent genital lesions and symptomatic days in animal models compared to other vaccines or placebo. It elicits robust cellular immune responses against HSV infection. The vaccine was originally created at Southern Illinois University School of Medicine and the University of Kansas, with development led by Rational Vaccines[1][3][6].
- Brand names
- Theravax
- Other names
- RVx 201RVx201RVx-201
Beyond the preview
Go deeper on RVx201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RVx201.